Osteoporosis/Musculoskeletal Health

Osteoporosis/Musculoskeletal Health
For Japanese Investigators only. Regional AOI included.
The following areas are of interest to Merck Investigator Studies Program Committee:
(PLEASE NOTE: No Odanacatib can be provided to independent investigators in 2015. In
addition, no selective rodent CatK inhibitors are available from Merck.)
Global AOI
•
Mechanistic studies to better understand the effects of Cathepsin K and/or its inhibition on
bone modeling and remodeling
•
Mechanistic studies to better understand the effects of Cathepsin K on collagen metabolism
•
Studies that assess non-density related bone properties and their relation to bone strength or
fracture risk, such as bone material properties or bone macro and microarchitecture,
including studies to validate new methodologies
•
Studies to characterize osteoporosis in men: including natural history, etiology, prevalence,
rates of diagnosis, treatment, and adherence
•
Studies that explore:
o
The effects of vitamin D, or its metabolites, on bone cells
o
The relationship between vitamin D status and BMD and/or the risk of osteoporotic
fractures in humans
Regional AOI for Japan
•
Studies to understand osteoporosis and/or increased bone fragility in patients with comorbid
diseases specifically: T2DM, CKD, COPD, etc. including natural history, etiology, prevalence
and outcomes.
Merck Investigator Studies Programサイト (クリックすると、Merck & Co., Incが運営する米国MISPウェ
ブサイトのAOI情報へジャンプします。)
Regional AOIは、その地域のニーズを取り入れて設定された独自のAOIです。
Regional AOIの申請手順／スケジュール／審査委員会は、Global AOIと同じです。
日本の申請窓口はMSD株式会社となります。申請をご検討の場合は、お早めに問合せ／資料請求先へ申
請資料をご請求ください。
以上

Download Report